Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase

References

• Alcorn JF, van der Velden J, Brown AL, McElhinney B, Irvin CG, Janssen-Heininger YMW. 2009. c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol. 40(4):422–432.
   PubMed Web of Science ®Google Scholar
• Bennett B, Blease K, Ye Y, Azaryan A, Ramirez-Valle F, Ceres R, Horan G, Schafer P, Van Der Velden JL, Janssen-Heininger YMW. 2017. CC-90001, a Second Generation Jun N-Terminal Kinase (JNK) inhibitor for the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 195:A5409.
   Web of Science ®Google Scholar
• Bosilkovska M, Samer C, Déglon J, Thomas A, Walder B, Desmeules J, Daali Y. 2016. Evaluation of mutual drug-drug interaction within geneva cocktail for cytochrome P450 phenotyping using innovative dried blood sampling method. Basic Clin Pharmacol Toxicol. 119(3):284–290.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu L, Laille E, Kumar G, Surapaneni S. 2010. In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine. Cancer Chemother Pharmacol. 65(5):995–1000.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang X, Tong Z, Reyes J, Carayannopoulos L, Zhou S, Li Y. 2021. Assessment of transporter-mediated drug interactions for enasidenib based on a cocktail study in patients with relapse or refractory acute myeloid leukemia or myelodysplastic syndrome. J Clin Pharmacol.DOI: https://doi.org/10.1002/jcph.1979
   Web of Science ®Google Scholar
• CHMP. 2012. Guideline on the investigation of drug interactions. EMA. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf
   Google Scholar
• Cho YY, Jeong HU, Kim JH, Lee HS. 2014. Effect of honokiol on the induction of drug-metabolizing enzymes in human hepatocytes. Drug Des Devel Ther. 8:2137–2145.
   PubMed Web of Science ®Google Scholar
• Davis RJ. 2000. Signal transduction by the JNK group of MAP kinases. Cell. 103(2):239–252.
   PubMed Web of Science ®Google Scholar
• Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien H-C, White N, Jennings SH, Choi SO, Li J, Wagner MJ, et al. 2010. A phenotype–genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 87(6):735–742.
   PubMed Web of Science ®Google Scholar
• FDA. 2020a. Guidance for industry: In Vitro drug interaction studies — cytochrome P450 Enzyme- and transporter-mediated drug interactions. https://www.fda.gov/media/134582/download
   Google Scholar
• FDA. 2020b. Guidance for industry: clinical drug interaction studies — cytochrome P450 enzyme- and transporter-mediated drug interactions. https://www.fda.gov/media/134581/download
   Google Scholar
• Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt J, Mol R, Mordenti J, Ouatas T. 2015. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 54(10):1057–1069.
   PubMed Web of Science ®Google Scholar
• Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu C-F, et al. 2010. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 88(5):652–659.
   PubMed Web of Science ®Google Scholar
• Gravel S, Chiasson JL, Gaudette F, Turgeon J, Michaud V. 2019. Use of 4β-hydroxycholesterol plasma concentrations as an endogenous biomarker of CYP3A activity: clinical validation in individuals with type 2 diabetes. Clin Pharmacol Ther. 106(4):831–840.
   PubMed Web of Science ®Google Scholar
• Hirota T, Fujita Y, Ieiri I. 2020. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol. 16(9):809–822.
   PubMed Web of Science ®Google Scholar
• Huang S-M, Temple R, Throckmorton DC, Lseko LJ. 2007. Drug interaction studies – study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther. 81(2):298–304.
   Google Scholar
• Kluwe J, Pradere J-P, Gwak G-Y, Mencin A, De Minicis S, Osterreicher CH, Colmenero J, Bataller R, Schwabe RF. 2010. Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology. 138(1):347–359.
   PubMed Web of Science ®Google Scholar
• Lipner MB, Peng XL, Jin C, Xu Y, Gao Y, East MP, Rashid NU, Moffitt RA, Loeza SGH, Morrison AB, et al. 2020. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. JCI Insight. 5(8):e129905.
   PubMed Web of Science ®Google Scholar
• Luedtke D, Marzin K, Jungnik A, von Wangenheim U, Dallinger C. 2018. Effects of ketoconazole and rifampicin on the pharmacokinetics of nintedanib in healthy subjects. Eur J Drug Metab Pharmacokinet. 43(5):533–541.
   PubMed Web of Science ®Google Scholar
• Madan A, Burton LA, Ogilvie BW, Parkinson A. 2002. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In: Rodrigues AD, editor. Drug-drug interactions. New York: Marcel Dekker, Inc.
   Google Scholar
• Nagy MA, Hilgraf R, Mortensen DS, Elsner J, Norris S, Tikhe J, Yoon W, Paisner D, Delgado M, Erdman P, et al. 2021. Discovery of CC-90001, a potent c-Jun N-terminal kinase (JNK) inhibitor for the treatment of fibrosis. J Med Chem. 64(24):18193–18208.
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. 2006. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos. 34(1):191–197.
   PubMed Web of Science ®Google Scholar
• Pearce RE, Mcintyre CJ, Madan A, Sanzgiri U, Draper AJ, Bullock PL, Cook DC, Burton LA, Latham J, Nevins C, et al. 1996. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys. 331(2):145–169.
   PubMed Web of Science ®Google Scholar
• Polli JW, Hussey E, Bush M, Generaux G, Smith G, Collins D, McMullen S, Turner N, Nunez DJ. 2013. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. Xenobiotica. 43(6):498–508.
   PubMed Web of Science ®Google Scholar
• Roh H, Son H, Lee D, Chang H, Yun C, Park K. 2014. Pharmacokinetic interaction between rosuvastatin and olmesartan: a randomized, open-label, 3-period, multiple-dose crossover study in healthy Korean male subjects. Clin Ther. 36(8):1159–1170.
   PubMed Web of Science ®Google Scholar
• Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME, Zimdahl-Gelling H, Gansser D, Wein M, Ebner T, et al. 2016. Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin. Clin Pharmacol Ther. 100(3):259–267.
   PubMed Web of Science ®Google Scholar
• Tong Z, Yerramilli U, Surapaneni S, Kumar G. 2014. The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug–drug interactions. Cancer Chemother Pharmacol. 73(4):869–874.
   PubMed Web of Science ®Google Scholar
• Topletz-Erickson AR, Lee AJ, Mayor JG, Rustia EL, Abdulrasool LI, Wise AL, Dailey B, DeChenne S, Walker LN, Alley SC, et al. 2021. Tucatinib inhibits renal transporters OCT2 and MATE without impacting renal function in healthy subjects. J Clin Pharmacol. 61(4):461–471.
   PubMed Web of Science ®Google Scholar
• Tucker GT, Houston JB, Huang SM. 2001. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res. 18(8):1071–1080.
   PubMedGoogle Scholar
• Walsky RL, Obach RS. 2004. Validated assays for human cytochrome P450 activities. Drug Metab Dispos. 32(6):647–660.
   PubMed Web of Science ®Google Scholar
• Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, Ifedigbo E, Xu X, Oury TD, Kaminski N, et al. 2006. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med. 203(13):2895–2906.
   PubMed Web of Science ®Google Scholar
• Wiebe ST, Giessmann T, Hohl K, Schmidt-Gerets S, Hauel E, Jambrecina A, Bader K, Ishiguro N, Taub ME, Sharma A, et al. 2020. Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil, and cimetidine. Clin Pharmacokinet. 59(12):1627–1639.
   PubMed Web of Science ®Google Scholar
• Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, Stopfer P, Dallinger C. 2019. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet. 58(9):1131–1147.
   PubMed Web of Science ®Google Scholar